Investigational drug · Phase 2
AD17002
Also called: LTh
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Eosinophilic Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 26, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "AD17002"
First trial start
2023
Nov 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "AD17002", any sponsor or status.
Conditions studied
As listed on its trial records.
- Eosinophilic Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "AD17002" as an intervention, largest first.
- Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19Pivotal-lookingTerminated
Advagene Biopharma Co. Ltd.Industry
NCT05541510 · 180 participants · Start Dec 1, 2022 · Primary completion Aug 5, 2024
Drug: AD17002 + Formulation buffer; Placebo · For: COVID-19
Sites: Kota Jkt Utara, Indonesia; Yogyakarta, Indonesia · 3 sites in all
- A Multi-dose Study on the Safety and Efficacy of Self-administered Intranasal AD17002 Treatment for Eosinophilic AsthmaPivotal-lookingNot yet recruiting
Advagene Biopharma Co. Ltd.Industry
NCT07250594 · 126 participants (planned) · Start Dec 2025 · Primary completion Oct 2026
Drug: AD17002 · For: Eosinophilic Asthma
Sites: Taipei, Taiwan
Advagene Biopharma Co. Ltd.Industry
NCT04088721 · 48 participants · Start Mar 26, 2019 · Primary completion Jul 30, 2020
Drug: AD17002 · For: Allergic Rhinitis
Sites: Taipei, Taiwan
Advagene Biopharma Co. Ltd.Industry
NCT05985694 · 40 participants · Start Nov 27, 2023 · Primary completion Jan 28, 2025
Drug: AD17002; Placebo · For: Eosinophilic Asthma
Sites: Taipei, Taiwan
Advagene Biopharma Co. Ltd.Industry
NCT05069610 · 30 participants · Start Mar 21, 2022 · Primary completion Oct 31, 2023
Drug: AD17002; Placebo (Formulation buffer) · For: COVID-19
Sites: Taipei, Taiwan; Taoyuan, Taiwan
Newest research
PubMed records naming it or its code names, newest first.
- Biomimetic nanocages with cascade homing for theranostics of ischemia-reperfusion acute kidney injury.
Xu Z, Wan Y, Shang Y, et al. · Mater Today Bio 2026
- OsPIL1 modulates growth-yield-blast resistance trade-offs involving OsINV3 and jasmonate signaling.
He P, Chen X, Chao Z, et al. · Plant Physiol 2026
- Random Sparse Networks Training With Sharpness-Aware Regularization.
Bai Y, Zhang M, Wang H, et al. · IEEE Trans Pattern Anal Mach Intell 2026
- S-Scheme charge transfer in topotactically transformed LTO/g-C3N4 for photo-Fenton mineralization in complex water matrices.
Alamro FS, Elsharkawy WB, Toghan A, et al. · RSC Adv 2026
- Dynamic metal-ligand coordination in solution: a ligand-exchange relay mechanism for gold(i) sulfido complex transformation.
Zhang Y, Li G, Yang M, et al. · Chem Sci 2026
- Fibroblastic Reticular Cell-Derived and CD5L-Enriched Exosomes Remodel Renal Lipid Metabolism in Porcine Sepsis-Associated Acute Kidney Injury.
Li Y, Wu W, Xu D, et al. · J Am Soc Nephrol 2026
Also in development for Eosinophilic Asthma
- Dexpramipexole DihydrochloridePhase 32 trials
Areteia Therapeutics · Chronic Obstructive Pulmonary Disease, Eosinophilic Asthma, Asthma; Eosinophilic
- KT-621Phase 23 trials
Kymera Therapeutics, Inc. · Eosinophilic Asthma, Atopic Dermatitis, Asthma (Diagnosis)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.